Table 2.

Baseline characteristics of the included studies

Author	Yr	Region	Arm	No.	Age (yr)	Male/female	NSAID	Aspirin	Antico-agulant	H. pylori positive	Comorbid disease	Gastric ulcer	Duodenal ulcer	Other ulcer3	Study population
Andriulli et al[16]	2008	European	High	238	66.3 ± 15.6	151/87	75	72	NA	NA	19	88	150	0	High-risk group1
			Low	236	66.8 ± 16.7	156/80	74	82	NA	NA	30	93	143	0
Yüksel et al[17]	2008	European	High	48	60.4 ± 14.0	38/10	19	22	NA	NA	21	16	32	0	High-risk group1
			Low	49	56.3 ± 17.6	36/13	20	25	NA	NA	16	16	33	1
Hung et al[2]	2007	Asia	High	54	63.7	32/22	6	9	NA	30	NA	19	35	0	High-risk group1
			Low	49	57.8	35/14	6	5	NA	33	NA	14	35	0
Lin et al[19]	2006	Asia	High	67	67	58/9	NA	NA	NA	48	53	26	35	6	High-risk group1
			Low	66	71	57/9	NA	NA	NA	51	50	29	33	4
Cheng et al[21]	2005	Asia	High	52	62.5 ± 12.5	36/16	13	1	2	27	52	28	19	5	Comorbid illnesses
			Low	53	65.8 ± 13.8	31/22	12	3	1	21	53	29	20	4
Dokas et al[9]	2004	European	High	10	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	High-risk group1
			Low	14	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Chilovi et al[24]	2003	European	High	46	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
			Low	45	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Udd et al[8]	2001	European	High	69	63.4 ± 15.7	41/28	37	7	10	46	55	39	30	0	Unselected2
			Low	73	66.0 ± 13.3	44/29	41	16	4	45	54	38	35	0
Schonekas et al[7]	1999	European	High	82	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
			Low	86	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

¹Included peptic ulcer patiens with spurting artery, ooze, non-bleeding visible vessel or adherent clot;

²Included peptic peptic ulcer patiens with spurting artery, ooze, non-bleeding visible vessel, adherent clot or black base;

³Include both gastral and duodenal ulcer, esophagal ulcer. H. pylori: Helicobacter pylori; NSAID: Non-steroidal anti-inflammatory drug; NA: Not available.